PubMed · 6889835
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P S Vinall, R E Oakey, J S Scott. 1982. Fetoplacental function tests.. https://doi.org/10.1177/000456328201900411
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Ovarian folliculogenesis is a dynamic process marked by exponential expansion and differentiation of the granulosa cells, oocyte maturation, ovulation and corpus luteum formation. Although the central roles of gonadotropins and gonadal steroids in this explosive agenda are well accepted, the variable fate of follicles afforded comparable stimulation within the same ovary suggests the existence of an additional intraovarian system comprised of regulating species that 'fine-tune' the blood-borne hormones.
Explore the source record for details and available documents.
PURPOSE: The history, mechanisms of action, efficacy and complications of estrogen therapy for prostate cancer are reviewed, and the current and future roles of estrogens in the treatment of prostate cancer are addressed. MATERIALS AND METHODS: An extensive review of the literature was done. RESULTS: Estrogens are effective in the treatment of advanced prostate cancer. High dose oral estrogens are associated with an increased risk of cardiovascular death. A dose of 1 mg. diethylstilbestrol daily is not associated with an increased risk of cardiovascular death. Estrogens are associated with other toxicities. Parenteral estrogens may not have the risk of cardiovascular death that is ascribed to oral estrogens. Estrogens have not been adequately compared to the combined androgen blockade regimen. CONCLUSIONS: A 1 mg. dose of diethylstilbestrol remains a medial alternative to bilateral orchiectomy in the treatment of advanced prostate cancer. Doses of 3 mg. diethylstilbestrol or more have a prohibitively high risk of cardiovascular death. Further studies comparing the efficacy, complications and cost of regimens containing oral estrogens or parenteral estrogens with agents that increase efficacy (for example antiandrogens) and decrease toxicity (for example anticoagulants) to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogen-containing regimen could lower the cost of treating advanced prostate cancer.